Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Sep 2025 value amounting to $37.1 million.

  • Catalyst Pharmaceuticals' Net Cash Flow fell 44.34% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.6 million, marking a year-over-year decrease of 22.96%. This contributed to the annual value of $379.9 million for FY2024, which is 336.33% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Net Cash Flow stood at $37.1 million, which was down 48.59% from $72.1 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Net Cash Flow high stood at $172.8 million for Q1 2024, and its period low was -$150.1 million during Q1 2023.
  • Its 3-year average for Net Cash Flow is $35.6 million, with a median of $63.1 million in 2025.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Net Cash Flow skyrocketed by 851.36% in 2021, and later plummeted by 2,267.58% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Net Cash Flow (Quarterly) stood at $16.6 million in 2021, then spiked by 154.86% to $42.3 million in 2022, then tumbled by 60.63% to $16.7 million in 2023, then soared by 351.38% to $75.2 million in 2024, then slumped by 44.34% to $37.1 million in 2025.
  • Its Net Cash Flow stands at $37.1 million for Q3 2025, versus $72.1 million for Q2 2025 and $63.1 million for Q1 2025.